The effects of Batroxobin on the intimal hyperplasia of graft veins - 29/09/13
, Jian Wang c, Cheng Chen d, Fan Zhou c, Yan Zhou b, Fangjie Zhang cAbstract |
Background |
To investigate the effects of Batroxobin (BX) on the intimal hyperplasia of graft veins.
Methods |
Twenty dogs were evenly divided into 2 groups. The femoral veins were grafted into the femoral artery by microsurgery, and the experimental group was treated with BX (0.1 BU/kg/48 hours). The serum level of endothelin-1 (ET-1) was detected 2 weeks after operation. Computer image analysis system was performed to calculate the cross-sectional area of neointima and media in the vein grafts 8 weeks after operation. Immunohistochemistry method was performed to identify proliferating cell nuclear antigen (PCNA) and c-Myc.
Results |
The experimental group had a lower level of serum ET-1 than the control group (P < .01), and both intimal hyperplasia and media thickness of graft veins were reduced by BX in comparison with the control group (P < .05). C-Myc expression was higher in the control group than in the experimental group (P < .01). The PCNA expression in the experimental group was significantly lower than the control group (P < .05).
Conclusions |
These findings suggested that BX could inhibit intimal hyperplasia through suppressing cell proliferation activity.
Le texte complet de cet article est disponible en PDF.Keywords : Autologous veins graft, Batroxobin, Intimal hyperplasia
Plan
| The authors declare no conflicts of interest. |
Vol 206 - N° 4
P. 594-598 - octobre 2013 Retour au numéro
Article précédent
- Risk factors contributing to the difference in prognosis for papillary versus micropapillary thyroid carcinoma
- Theodore Karatzas, Ioannis Vasileiadis, Stylianos Kapetanakis, Efthimios Karakostas, George Chrousos, Gregory Kouraklis
- Feedback activities of instructors during a trauma surgery course
- Alexander Alken, Edward Tan, Jan-Maarten Luursema, Cornelia Fluit, Harry van Goor
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?